JP2015501808A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501808A5
JP2015501808A5 JP2014543550A JP2014543550A JP2015501808A5 JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5 JP 2014543550 A JP2014543550 A JP 2014543550A JP 2014543550 A JP2014543550 A JP 2014543550A JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5
Authority
JP
Japan
Prior art keywords
solid oral
oral pharmaceutical
compound
formulation
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501808A (ja
JP6216325B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066185 external-priority patent/WO2013078264A1/en
Publication of JP2015501808A publication Critical patent/JP2015501808A/ja
Publication of JP2015501808A5 publication Critical patent/JP2015501808A5/ja
Application granted granted Critical
Publication of JP6216325B2 publication Critical patent/JP6216325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543550A 2011-11-23 2012-11-21 医薬製剤 Active JP6216325B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017182214A Division JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Publications (3)

Publication Number Publication Date
JP2015501808A JP2015501808A (ja) 2015-01-19
JP2015501808A5 true JP2015501808A5 (cg-RX-API-DMAC7.html) 2016-01-14
JP6216325B2 JP6216325B2 (ja) 2017-10-18

Family

ID=47501412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543550A Active JP6216325B2 (ja) 2011-11-23 2012-11-21 医薬製剤
JP2017182214A Pending JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017182214A Pending JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Country Status (38)

Country Link
US (4) US9387208B2 (cg-RX-API-DMAC7.html)
EP (2) EP2782557B1 (cg-RX-API-DMAC7.html)
JP (2) JP6216325B2 (cg-RX-API-DMAC7.html)
KR (1) KR102091295B1 (cg-RX-API-DMAC7.html)
CN (2) CN103945831A (cg-RX-API-DMAC7.html)
AR (1) AR088936A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012340759C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014011981B8 (cg-RX-API-DMAC7.html)
CA (1) CA2856406C (cg-RX-API-DMAC7.html)
CL (1) CL2014001337A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940426A2 (cg-RX-API-DMAC7.html)
CY (1) CY1121421T1 (cg-RX-API-DMAC7.html)
DK (1) DK2782557T3 (cg-RX-API-DMAC7.html)
EA (1) EA025389B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP23034537A (cg-RX-API-DMAC7.html)
ES (2) ES2695099T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400100A (cg-RX-API-DMAC7.html)
HR (1) HRP20181896T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040370T2 (cg-RX-API-DMAC7.html)
IL (1) IL232305B (cg-RX-API-DMAC7.html)
JO (1) JO3493B1 (cg-RX-API-DMAC7.html)
LT (1) LT2782557T (cg-RX-API-DMAC7.html)
MA (1) MA35716B1 (cg-RX-API-DMAC7.html)
MX (1) MX353446B (cg-RX-API-DMAC7.html)
MY (1) MY172729A (cg-RX-API-DMAC7.html)
PE (1) PE20141994A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501157A1 (cg-RX-API-DMAC7.html)
PL (1) PL2782557T3 (cg-RX-API-DMAC7.html)
PT (1) PT2782557T (cg-RX-API-DMAC7.html)
RS (1) RS58048B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401260QA (cg-RX-API-DMAC7.html)
SI (1) SI2782557T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800595T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000145A1 (cg-RX-API-DMAC7.html)
TW (1) TWI649098B (cg-RX-API-DMAC7.html)
UA (1) UA115039C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013078264A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402418B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017210538A1 (en) 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (en) 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1000055A1 (en) 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
JP5159012B2 (ja) 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
RU2006128788A (ru) 2004-01-09 2008-02-20 Новартис АГ (CH) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP2009504796A (ja) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト pH依存性薬剤化合物、pH調整剤および遅延剤を含む医薬組成物
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN101522661A (zh) 2006-10-02 2009-09-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101522026A (zh) 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 raf 억제제로서 이의 용도
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR20130040258A (ko) 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
JP5490137B2 (ja) 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012017705B1 (pt) 2010-01-27 2020-03-24 Nerviano Medical Science S.R.L. Derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CN103442715A (zh) 2011-03-21 2013-12-11 瓦尔库里亚公司 包括hdac抑制剂以及类固醇的药用组合物及其用途
SG195141A1 (en) 2011-06-14 2013-12-30 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Similar Documents

Publication Publication Date Title
JP2015501808A5 (cg-RX-API-DMAC7.html)
JP6216325B2 (ja) 医薬製剤
US9907789B2 (en) Sustained-release preparation
ES2674811T3 (es) Composiciones estables de fesoterodina
KR101093781B1 (ko) pH조절제를 함유하는 목시플록사신 고형 조성물
EP2839829B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
JP2021518422A (ja) レナリドミドを含む医薬組成物
JP2022140430A (ja) リバーロキサバン含有錠剤
HK40005622A (en) Pharmaceutical formulations
NZ623628B2 (en) Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)
TW201729814A (zh) 固形製劑
HK1197024B (en) Pharmaceutical formulations
NZ713151B2 (en) Sustained-release formulations of colchicine and methods of using same
NZ713151A (en) Sustained-release formulations of colchicine and methods of using same